Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.10.19
Views: 172

Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain

Dr Ana Arance speaks to ecancer at ESMO 2019 in Barcelona about the Checkmate 067 trial.

This trial looks at nivolumab plus ipilimumab combination therapy in advanced melanoma, and at ESMO 2019 we saw the 5 year survival outcomes.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation